Lysosomes key to coronavirus shedding, finds study
Scientists reveal that coronaviruses de-activate lysosomes before using them to exit infected cells and spread through the body.
List view / Grid view
Scientists reveal that coronaviruses de-activate lysosomes before using them to exit infected cells and spread through the body.
Using lung organoids, researchers have shown that 48 hours after SARS-CoV-2 infection, the innate immune response began.
Enosi Life Science researchers Sir Marc Feldmann, Dr H Michael Shepard and Dr Fiona McCann explain why anti-TNF therapies may be effective in treating COVID-19 associated cytokine storms and other inflammatory conditions.
Researchers reveal that SARS-CoV-2 is more infectious than SARS-CoV because it can use both ACE2 and neuropilin-1 to infect cells.
Researchers have found that CBD reduces inflammation in the lungs of COVID-19 mouse models by increasing levels of the apelin peptide.
Scientists suggest targeting the SARS-CoV-2 papain-like protease (PLpro) with inhibitors could prevent the spread of infection.
Researchers suggest that targeting host proteins with drugs, rather than directly targeting enzymes or proteins on SARS-CoV-2 and related coronaviruses, could improve outcomes.
A team has identified 219 molecules and genes that influence the severity of COVID-19 in patients, providing information that could aid the development of therapeutics.
A team showed that high doses of favipiravir can treat hamsters infected with SARS-CoV-2, whereas hydroxychloroquine has no effect.
A team has said that inhibiting the factor D protein could prevent SARS-CoV-2 from turning the immune system against healthy cells.
Researchers have found that the surface of SARS-CoV-2 can take on at least 10 different structural states when in contact with ACE2.
Breaking down or slowing the production of a hyaluronan jelly which builds up in the lungs of some severe COVID-19 patients could reduce respiratory distress and prevent death.
Researchers have posited that SARS-CoV-2 could be combatted by sofosbuvir, in combination with other antivirals such as remdesivir.
The nitric oxide treatment used during the 2003 SARS epidemic could be used as an antiviral against SARS-CoV-2, researchers say.
Researchers studied 180 convalescent COVID-19 patients to reveal T-cell epitopes that they say can be targeted by a vaccine.